Skip to main content

Table 2 Summary of phenotypes in whole-lung cells of bleomycin (BLM)- or BLM + pirfenidone-treated mice determined through fluorescence-activated cell sorter analysis in a therapeutic setting *

From: Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis

 

Percentage of cells

Treatment

CD45-/Col-I-

CD45+/Col-I-

CD45-/Col-I+

CD45+/Col-I + (Fibrocyte)

Saline

64.8 ± 9.5

9.76 ± 13.6

15.3 ± 21.4

10.1 ± 1.7

BLM

25.1 ± 3.0

16.1 ± 22.0

33.1 ± 25.0

25.6 ± 5.9

BLM + pirfenidone

47.8 ± 7.2

6.8 ± 8.7

27.8 ± 7.8

17.6 ± 6.4

  1. *Data are shown as the percentage of cells that are positive (+) or negative (−) for CD45 or collagen I (Col-I) in whole-lung cells. Data shown represent the means ± standard error from 6 saline-, BLM- or BLM + pirfenidone-treated mice, respectively, and are representative of 2 independent experiments.